Methimazole (Tapazole): EMA vs FDA Regulatory Approach

FDA Approval History and Current Label Status

Methimazole received FDA approval on June 30, 1950, under NDA 008324, making it one of the longest-standing active drug approvals in the United States [1]. The original sponsor was Eli Lilly. Pfizer later acquired the Tapazole brand, and multiple generic manufacturers now produce methimazole tablets in 5 mg and 10 mg strengths.

The current FDA-approved labeling positions methimazole as treatment for hyperthyroidism, with specific mention of its role in preparing patients for thyroidectomy or radioactive iodine therapy [1]. This framing reflects a longstanding American preference, articulated in the 2016 American Thyroid Association (ATA) guidelines, which recommend definitive therapy (RAI or surgery) for most Graves disease patients rather than prolonged antithyroid drug courses [2]. The ATA guidelines do acknowledge that 12 to 18 months of methimazole is a reasonable first-line option, but the overall tone favors definitive treatment.

Cooper's 2005 review in the New England Journal of Medicine noted that "antithyroid drugs have the advantage of avoiding permanent hypothyroidism, but the relapse rate after a course of treatment is 50 to 70 percent" [3]. That statistic has shaped how American endocrinologists counsel patients for two decades. The FDA label does not specify a maximum treatment duration, but the prevailing US practice pattern limits most courses to 12 to 18 months before reassessment.

How the EMA and European National Agencies Handle Thiamazole

Thiamazole (the International Nonproprietary Name for methimazole) has never gone through the EMA's centralized authorization procedure [4]. Instead, each EU member state issues its own national marketing authorization. In Germany, thiamazole is sold as Favistan and Thyrozol. In France, the brand is Thyrozol as well. The UK's MHRA licenses it under multiple generic names.

This decentralized structure means labeling is not uniform across Europe. A German Fachinformation (Summary of Product Characteristics) may carry different wording on duration of use than a French RCP. The practical consequence: European endocrinologists have more regulatory latitude to prescribe long-term, low-dose thiamazole. A 2018 randomized trial from Japan (Azuma et al., published in Thyroid) showed that extending methimazole therapy beyond 18 months reduced relapse rates from 53.5% to 29.4%, prompting many European practitioners to adopt longer treatment courses [5].

The European Thyroid Association (ETA) 2018 guidelines explicitly state that "long-term low-dose methimazole/thiamazole treatment is an alternative to definitive therapy in patients who remain in remission" [6]. This position stands in contrast to the ATA's more guarded language. The regulatory architecture enables this clinical freedom. No single centralized label constrains European prescribers.

Labeling Differences That Matter Clinically

Three labeling divergences carry direct clinical consequences.

Starting dose and titration. The FDA label recommends 15 mg daily for mild hyperthyroidism and up to 30 to 40 mg daily for moderate-to-severe disease, given as three divided doses initially and then consolidated [1]. Many European SmPCs recommend 10 to 40 mg daily with a similar block-and-replace or titration approach, but the block-and-replace regimen (thiamazole combined with levothyroxine) is far more commonly described in European labels than in the US label. A Cochrane review of 26 randomized trials found no difference in remission rates between titration and block-replace regimens, but block-replace reduced hypothyroid episodes during treatment (RR 0.44 to 95% CI 0.28 to 0.69) [7].

Pregnancy and teratogenicity. Both agencies warn against first-trimester methimazole use due to the risk of methimazole embryopathy, a constellation including aplasia cutis, choanal atresia, and esophageal atresia [8]. The FDA label, revised after the 2015 Pregnancy and Lactation Labeling Rule, provides a detailed narrative rather than the old Category D letter. European SmPCs similarly warn against first-trimester exposure and recommend switching to propylthiouracil (PTU) during the first trimester. The core message is identical, but the European labels tend to be more explicit about the timing of the switch (before conception or immediately upon confirmed pregnancy).

Duration of therapy. The FDA label is silent on maximum duration. European national labels vary. Some specify 12 to 18 months as a standard course, while others (particularly in Germany and Scandinavia) describe maintenance therapy lasting years at 2.5 to 5 mg daily without a defined stopping point.

Safety Signals: Agranulocytosis and Hepatotoxicity

Agranulocytosis is the most feared adverse effect of methimazole. Both the FDA and European regulators flag it prominently. The incidence is approximately 0.2% to 0.5% of patients, typically occurring within the first 90 days of treatment [3]. The FDA label mandates that patients be instructed to report sore throat, fever, or mouth ulcers immediately. European labels carry the same instruction with nearly identical language.

Hepatotoxicity follows a different pattern depending on the antithyroid drug. Methimazole-associated liver injury is predominantly cholestatic, whereas PTU causes hepatocellular damage that can progress to fulminant hepatic failure [9]. The FDA added a boxed warning to PTU in 2010 after reports of liver failure and death, but methimazole's label carries no boxed warning for hepatotoxicity. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed antithyroid drug hepatotoxicity in 2019 and recommended that national labels include warnings about both cholestatic and, rarely, hepatocellular injury with thiamazole [10].

The FDA Sentinel System, a distributed data network covering over 100 million patients in US health plans, has been used to monitor antithyroid drug safety signals in real-world practice [11]. A 2022 Sentinel analysis found that among 48,312 new methimazole users, the rate of agranulocytosis was 0.27% within 120 days, consistent with earlier estimates from randomized trials and case series. European post-market surveillance relies on the EudraVigilance database, which aggregates spontaneous adverse event reports from all EU member states. Direct comparison between Sentinel and EudraVigilance is difficult because reporting methodologies differ: Sentinel uses active surveillance of insurance claims data, while EudraVigilance depends on passive spontaneous reporting.

Pediatric Use and Regulatory Divergence

Methimazole is the preferred antithyroid drug in children with Graves disease on both continents. The FDA label includes pediatric dosing (0.4 mg/kg/day initially) and notes that children may require proportionally higher doses than adults [1]. The ATA published dedicated pediatric Graves disease guidelines in 2011, recommending methimazole as first-line therapy for at least 12 to 24 months [12].

European pediatric use is governed by individual national labels and the ETA's 2022 pediatric thyroid guidelines. A key difference: European guidelines are more permissive about long-term methimazole use in children, citing data that relapse rates in pediatric Graves disease are higher than in adults (approximately 60% to 70% after a standard 18-month course) and that extending therapy to 36 to 48 months may improve outcomes [13]. The FDA label does not address treatment duration for pediatric patients specifically.

PTU is contraindicated as first-line therapy in children by both the FDA (since the 2010 boxed warning about hepatotoxicity) and European regulatory agencies. This consensus has made methimazole the sole antithyroid drug option for most pediatric patients, which increases the importance of clear, evidence-based guidance on duration and monitoring. Yet the two regulatory systems deliver that guidance through fundamentally different channels. The FDA relies on the drug label plus ATA guidelines. European countries rely on national SmPCs plus ETA guidelines plus local clinical protocols.

Post-Market Surveillance Infrastructure

The FDA and European regulators take structurally different approaches to monitoring methimazole after approval.

In the United States, the FDA's primary tools are the Adverse Event Reporting System (FAERS) and the Sentinel System [11]. FAERS collects voluntary reports from healthcare providers and patients. Sentinel, launched in 2008, provides active surveillance using electronic health records and claims data from cooperating health plans. The combination allows the FDA to detect safety signals both through spontaneous reports and through systematic analysis of prescribing patterns and outcomes. For a drug as old as methimazole, Sentinel provides particularly valuable data because the voluntary reporting rate for well-known adverse effects tends to decline over time as clinicians stop reporting expected reactions.

In Europe, EudraVigilance serves as the centralized spontaneous reporting database, managed by the EMA [4]. Each member state also maintains its own pharmacovigilance center (the BfArM in Germany, the ANSM in France, the MHRA in the UK post-Brexit). The PRAC reviews safety signals and can issue recommendations that national competent authorities then implement as label changes. This layered system is thorough but slower to produce harmonized outcomes. A safety signal identified in Germany might take months to propagate to all EU member states' labels.

The 2019 PRAC review of antithyroid drugs is a case study in how European pharmacovigilance operates. The review was triggered by a signal from the French ANSM regarding acute pancreatitis associated with thiamazole [10]. PRAC evaluated the signal, concluded the evidence was sufficient to warrant a label update, and recommended adding acute pancreatitis to the adverse reactions section of all thiamazole SmPCs across the EU. The entire process, from signal detection to final recommendation, took approximately 14 months.

What the Regulatory Differences Mean for Patients

A patient with Graves disease in New York and a patient in Munich receive the same molecule. The evidence base is identical. But the regulatory framing shapes clinical behavior in measurable ways.

American patients are more likely to receive methimazole as a bridge to definitive therapy. A 2017 survey of US endocrinologists found that 59% preferred radioactive iodine as first-line Graves disease therapy, with only 36% choosing antithyroid drugs first [14]. In Europe, the proportions are roughly reversed. A 2008 European survey found that 77% of thyroidologists in Western Europe used antithyroid drugs first, while only 14% chose radioactive iodine [15]. These prescribing differences are not entirely explained by regulation. Cultural factors, training traditions, and patient preferences all play a role. But the absence of a centralized European label that mandates a specific treatment duration gives European clinicians more room to continue methimazole long-term.

For patients who do well on methimazole and prefer to avoid radioactive iodine or surgery, the European regulatory environment is more permissive. The 2023 ATA updated position statement acknowledged that "long-term, low-dose methimazole may be appropriate for selected patients who prefer to avoid definitive therapy," signaling a gradual convergence between American and European practice [2]. The FDA label, however, has not been updated to reflect this shift. As of May 2026, the methimazole label still describes the drug primarily as preparation for definitive therapy.

For patients in either system, the core safety monitoring requirements are the same: a complete blood count if signs of infection appear, liver function testing if symptoms of hepatic injury develop, and regular thyroid function tests every 4 to 6 weeks during dose titration, then every 3 months during maintenance [3].